Valeant gains more ground; Atlantic Power, MGM Growth, American Renal update deals

By Sara Rosenberg

New York, April 6 – Valeant Pharmaceuticals International Inc.’s term loans continued to climb higher in trading on Wednesday on the back of amendment proposal changes and an update on restatements and helped by a generally improved market tone.

Valeant’s term loans E and F were quoted at 96 bid, 96½ offered, up from 95 5/8 bid, 96 3/8 offered, the term loans C and D were quoted at 96¼ bid, 97 offered, up from 95 5/8 bid, 96 3/8 offered, and the term loan A3 was quoted at 96½ bid, 97½ offered, up from 95½ bid, 97 offered, one trader remarked.

Meanwhile, a second trader had the term loans E and F quoted at 96¼ bid, 97 offered, up from 95¾ bid, 96½ offered on Tuesday.

On Monday, the term loans E and F were quoted at 94 bid, 95 offered, the term loans C and D were quoted at 94¾ bid, 95¾ offered, and the term loan A3 was quoted at 95¼ bid, 96¼ offered.

Switching to the primary market, Atlantic Power LP (APLP Holdings LP) widened pricing and original issue discount on its term loan B while also sweetening the project finance quarterly cash flow sweep, and MGM Growth Properties Operating Partnership LP firmed spread and issue price on its term loan B at the tight end of revised talk.

Also, American Renal Holdings Inc. finalized the original issue discount on its add-on first-lien term loan at the tight side of guidance.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.